Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination

    TORONTO, June 2 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today
announced that data demonstrating the clinical utility of its EAA(TM)
Endotoxin Activity Assay in combination with Toray Medical's therapeutic
column, Toraymyxin, was presented at the Practical Aspects of Extracorporeal
Blood Purification in Intensive Care Medicine, 6th Annual Conference held in
Moscow, Russia from May 28th-30th.
    Dr. Alexander Romaschin, Head of Clinical Biochemistry at St. Michael's
Hospital in Toronto and Associate Professor in the Department of Lab Medicine
and Department of Surgery at University of Toronto, presented on the
effectiveness of sepsis patient management with the use of the combination of
Spectral's EAA(TM) assay, the only FDA cleared diagnostic for the measurement
of endotoxin, and the Toraymyxin(TM) column, which removes endotoxin from the
bloodstream. Dr. Romaschin's presentation was entitled "Diagnostic and
Prognostic Implications of Endotoxemia based on Measurements Using the
Endotoxin Activity Assay". In addition, Dr. Hisataka Shoji presented data from
the Japanese experience using the EAA/Toraymyxin combination.
    "There was great enthusiasm for this approach to managing sepsis patients
from this prestigious audience of medical doctors from across Russia," said
Rob Verhagen, Vice President, Business Development of Spectral. Spectral
recently announced that it has expanded its collaboration agreement with Toray
to include Russia.
    "Dr. Romaschin's data reaffirms the clinical utility of EAA(TM) in
combination with extracorporeal blood purification devices, such as
Toraymyxin(TM). This combination is gaining increasing recognition and
acceptance globally as an effective way to diagnose, treat and monitor
patients with endotoxemia," added Dr. Paul Walker, President and CEO of

    About Toraymyxin

    Toraymyxin, a blood purification device, absorbs the bacterial toxin
(endotoxin) that causes sepsis and septic shock using a special fiber. It
consists of a plastic cylindrical container filled with a special fiber
composite immobilized with the antibiotic polymyxin B, which has high affinity
for endotoxin. In 1993, Toray received approval for manufacturing and
marketing of the product from the "Health and Welfare Ministry of Japan," and
Toray Medical has been marketing it since 1994.

    About Toray

    Toray Medical Co., Ltd. is a subsidiary company of Toray Industries,
Inc., a leading diversified chemicals corporate group that has been
technology-focused since its foundation in 1926. The company's operations are
underpinned by technological expertise in organic synthetic chemistry, polymer
chemistry, and biochemistry. These innovative technologies have yielded
"advanced materials" that Toray is now exploiting to provide customers with
comprehensive solutions through Fibres and Textiles, Plastics and Chemicals,
IT-related Products, Carbon Fibre Composite Materials, Environment and
Engineering, Life Science and Other Business divisions. In FY2006, Toray had
consolidated sales of 1,546 billion yen (approx $13 billion US), and over
33,000 employees worldwide. For further information, please check

    About Spectral Diagnostics

    Spectral is a leader in the battle against sepsis. Spectral's lead
product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay
for the measurement of Endotoxin. With the growing awareness for the role of
Endotoxemia in sepsis and the increasing number of therapies being developed
for this indication, Spectral is well-positioned to drive the adoption of the
EAA(TM), which can be used to identify patients, enable therapeutics and
monitor treatment. Spectral is listed on TSX under the symbol SDI.

    Forward-looking statement

    Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

    %SEDAR: 00002006E

For further information:

For further information: Dr. Paul Walker, President & CEO, (416)
626-3233 ex. 2100; James Smith, Investor Relations, (416) 815-0700 ext. 229,

Organization Profile

Spectral Diagnostics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890